Product Description
Mechanisms of Action: Phosphate Binder
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: European Medicines Agency | Germany | Ireland | Italy | Portugal | Sweden | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Mitsubishi Tanabe
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Kidney Failure, Chronic|Hyperphosphatemia|Dyslipidemia|Kidney Diseases
Phase 2: Type 2 Diabetes
Phase 1: Hyperphosphatemia|Kidney Failure, Chronic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2012-002583-27 | P3 |
Terminated |
Hyperphosphatemia|Kidney Diseases |
2017-01-11 |
|
2012-002581-12 | P3 |
Completed |
Hyperphosphatemia|Kidney Diseases |
2015-01-26 |
|
MCI-196-E14 | P3 |
Terminated |
Kidney Failure, Chronic|Hyperphosphatemia |
2015-01-01 |
|
2012-002582-35 | P3 |
Terminated |
Hyperphosphatemia|Kidney Diseases |
2014-12-17 |